{"title": "In Investigational Study, ZOSTAVAX\u00ae, Merck's Shingles Vaccine, Reduced Incidence of Shingles in Adults Ages 50 to 59", "author": null, "url": "https://www.fiercepharma.com/pharma/investigational-study-zostavax%C2%AE-merck-s-shingles-vaccine-reduced-incidence-of-shingles", "hostname": "fiercepharma.com", "description": "Merck filed application for use in this age group earlier this year VANCOUVER, British Columbia--(BUSINESS WIRE)-- In a large clinical study of adults ages 50 to 59, ZOSTAVAX\u00ae (Zoster Vaccine Live), | Merck filed application for use in this age group earlier this year VANCOUVER, British Columbia--(BUSINESS WIRE)-- In a large clinical study of adults ages 50 to 59, ZOSTAVAX\u00ae (Zoster Vaccine Live),", "sitename": "FiercePharma", "date": "2010-10-21", "cleaned_text": "Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Subscribe Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us "}